Albumedix has extended its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International company.
Albumedix Ltd. completed the expansion of its commercial-scale manufacturing facility, alongside with the establishment of a new Technology Centre equipped with state-of-the-art labs at its UK-based campus in Nottingham.
Novartis will partner with Albumedix, a U.K-based specialist in recombinant human albumin, to explore using the company’s technology as a possible drug delivery platform for several therapies.